PTCrSBr08a (06-03.)
Approved for use through 07/31/2006 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a golilection of information unless if contains a valid OMB control number.

English translation of

abstract only

×

Jang, Soon Wook

Application Number 10595022
Filing Date 2005-12-19
First Named Inventor Chara (LEC, Gyunggi
Art Unit
Examiner Name
Attorney Coalet Number | PATLE-004

					U.S.I	PATENTS			
Examiner Initial*	Cite No				Pages,Columns,Lines where Relevant Passages or Releva Figures Appear				
	1	4065873		1978-01	1-83	Robert Alexander Jones			
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		
			U.S.P	ATENT	APPLK	CATION PUB	LICATIONS		
Examiner Initial*			entee or Applicant ment Pages, Columns, Lines w Relevant Passages or F Figures Appear						
	1								
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication	citation	ninformation	please click the Ad	d button.	
				FOREK	SN PAT	ENT DOCUM	IENTS		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr	y Code²	Kind Code4	Publication Date	Name of Patente Applicant of cited Document		TK
	1	08103571	JP				Kiyoushi You KK	English translation of abstract only	×
	2	1020020020562	KR				Shin, Duck Hoe	English translation of abstract only	×

19990014324

KR

If you wish to add additional Foreign Patent Document citation information please click the Add button

	· ++			
	Filing Date		2005-12-19	
INFORMATION DISCLOSURE	First Named Inventor	Chan	g LEE, Gyunggi	
(Not for submission under 37 CFR 1.99)	Art Unit			
(Not for additional direction of the 1.55)	Examiner Name			
	Attorney Docket Numb	er	PATLP-004	
NON	DATENT I ITERATIIRE	DOCI	IMENTS	

Application Number

10606022

(when appropriate), title of the item

T5

HORT ATERT ETERATORE BOOGMENT
 include name of the author (in CAPITAL LETTERS), title of the article

Initials*	No	(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s publisher, city and/or country where published.

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

EXAMINER SIGNATURE Date Considered

English lenguage translation is attached.

Examiner Signature Date Considered FEXAMINER: nitral if reference considered, whether or not citation is in conformance with MEPF 909. Draw line through a citation if not nonformance and not considered, include copy of this form with next communication to applicant.

See Not Codes of USPTO Pears Documents in year USPTO-000 or MPEP 011.04. Total critical the listend the document, by the hor-better code (NIPO) Sended 513. The species parted observers, as indicated of the year of the dispect maniprocess the seed another of the plant observer. "Word of potential by the approaches which is included on the contract enter NIPO Securities (Securities Code)." A registeral to spece or etch minth and the contract enter NIPO Securities (Securities Code).

	Filing Date		2005-12-19	
INFORMATION DISCLOSURE	First Named Inventor	Chan	g LEE, Gyunggi	
(Not for submission under 37 CFR 1.99)	Art Unit			
(Not for submission under 37 CFR 1.59)	Examiner Name			
	Attorney Docket Numb	er	PATLP-004	
	CERTIFICATION STAT	TEMEN	NT	

10595022

Application Number

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

OR

statement.

None

Name/Print

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CPR 1.56(c) more than these months prior to the filing of the information disclosure.

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE
A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the

A signature of the ap form of the signature.	plicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
Signature	Date (YYYY-MM-DD)

Registration Number

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confridentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including galettine, preparing and submilling the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the buries, should be sent to the Chief Information Orlinor, U.S. Pattent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22315-1450, D.D. NOT SCR. LEES OR COMPLETED FORMS TO 1184 SADPERS. S. SEM TO: Commissioner for Pattents, P.O. Box 1450, Alexandria,

Privacy Act Statement

The Privary Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicidal is voluntary, and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient agreement of the principal purpus submission related to a patient agreement of the patient. If you do not furnish the requested requirement of the principal purpus submission related to a patient agreement of the patient. If you do not furnish the requested requirement of the patient of the patient and the patient of the patient of the patient and the patient of the patient and the patient of the p

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Racipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(ci)).
 - 7. A record from this system of records may be disclosed, as a noutine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other intervent (i.e., GSA or Commerco) directive. Such disclosure shall not be used to make determinations about intrivivations.
 - A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 125(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a notification, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.